1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 4
FEATURED COMPANIES
- Astellas Pharma Inc.
- AstraZeneca
- Eli Lilly and Company
- Novartis AG
- MORE
Any genitourinary disorders are noted in the urinary tract and the genital organs. The conditions in these parts of the human body could occur due to various bacterial infections or STDs. Genitourinary ailments also include various cardnomas such as prostate cancer, ovarian cancer, bladder cancer, and cervical cancer. The prevalence of these conditions is high worldwide and is continuously increasing. Lifestyle disorders such as stroke, autoimmune conditions such as multiple sclerosis, obesity, diabetes, or age-related ailments such as Alzheimer's are significantly responsible for genitourinary conditions. The prevalence of such health conditions is rising globally due to the sedentary lifestyle. Such a high prevalence of genitourinary diseases will drive the market growth during the forecast period. The analysts have predicted that the genitourinary drugs market will register a CAGR of almost 3% by 2023.
Market Overview
Technological advances in diagnostics
Advances in technology help in increasing patient adherence to treatment and gaining effective and swift results. They help in improving the condition of patients and reducing the diagnostic time. With the recent advances, both in the molecular laboratory diagnosis and point-of-care (POC) diagnostics technology, the vendors of the global genitourinary drugs market are also providing effective and quick results with less cost.
Patent expiries of novel drugs
Patent expiries of novel therapeutics lead to the introduction of generic drugs. Therefore, generic drugs are more cost-effective than novel therapeutics. Patents of many novel drugs used for the treatment of genitourinary conditions have expired, and a few of them are about to lapse during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the genitourinary drugs market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be moderately fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Market Overview
Technological advances in diagnostics
Advances in technology help in increasing patient adherence to treatment and gaining effective and swift results. They help in improving the condition of patients and reducing the diagnostic time. With the recent advances, both in the molecular laboratory diagnosis and point-of-care (POC) diagnostics technology, the vendors of the global genitourinary drugs market are also providing effective and quick results with less cost.
Patent expiries of novel drugs
Patent expiries of novel therapeutics lead to the introduction of generic drugs. Therefore, generic drugs are more cost-effective than novel therapeutics. Patents of many novel drugs used for the treatment of genitourinary conditions have expired, and a few of them are about to lapse during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the genitourinary drugs market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be moderately fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- Astellas Pharma Inc.
- AstraZeneca
- Eli Lilly and Company
- Novartis AG
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 07: MARKET SEGMENTATION BY TYPE
PART 09: GEOGRAPHIC LANDSCAPE
PART 11: DRIVERS AND CHALLENGES
PART 13: VENDOR LANDSCAPE
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ billions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global genitourinary drugs market pipeline: Overview
Exhibit 18: Global genitourinary drugs market pipeline: Overview
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Genital diseases - Market size and forecast 2018-2023 ($ billions)
Exhibit 22: Syphilis cases reported in US 2013-2017
Exhibit 23: Genital diseases - Year-over-year growth 2019-2023 (%)
Exhibit 24: Urinary diseases - Market size and forecast 2018-2023 ($ billions)
Exhibit 25: Urinary diseases - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ billions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ billions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ billions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ billions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Prevalence of various genitourinary cancers in US 2015
Exhibit 45: Prevalence rate of urinary incontinence in the geriatric population in the US (2010)
Exhibit 46: Global geriatric population in the last 5 years
Exhibit 47: Trending advanced diagnostics
Exhibit 48: Recent approvals of generic drugs
Exhibit 49: Devices for the treatment of genitourinary diseases
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Trending novel formulations
Exhibit 52: Vendor landscape
Exhibit 53: Landscape disruption
Exhibit 54: Vendors covered
Exhibit 55: Vendor classification
Exhibit 56: Market positioning of vendors
Exhibit 57: Astellas Pharma Inc. - Vendor overview
Exhibit 58: Astellas Pharma Inc. - Business segments
Exhibit 59: Astellas Pharma Inc. - Organizational developments
Exhibit 60: Astellas Pharma Inc. - Geographic focus
Exhibit 61: Astellas Pharma Inc. - Key offerings
Exhibit 62: Astellas Pharma Inc. - Key customers
Exhibit 63: AstraZeneca - Vendor overview
Exhibit 64: AstraZeneca - Business segments
Exhibit 65: AstraZeneca - Organizational developments
Exhibit 66: AstraZeneca - Geographic focus
Exhibit 67: AstraZeneca - Key offerings
Exhibit 68: AstraZeneca - Key customers
Exhibit 69: Eli Lilly and Company - Vendor overview
Exhibit 70: Eli Lilly and Company - Business segments
Exhibit 71: Eli Lilly and Company - Organizational developments
Exhibit 72: Eli Lilly and Company - Geographic focus
Exhibit 73: Eli Lilly and Company - Segment focus
Exhibit 74: Eli Lilly and Company - Key offerings
Exhibit 75: Eli Lilly and Company - Key customers
Exhibit 76: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 77: Johnson & Johnson Services, Inc. - Business segments
Exhibit 78: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 79: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 80: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 81: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 82: Johnson & Johnson Services, Inc. - Key customers
Exhibit 83: Novartis AG - Vendor overview
Exhibit 84: Novartis AG - Business segments
Exhibit 85: Novartis AG - Organizational developments
Exhibit 86: Novartis AG - Geographic focus
Exhibit 87: Novartis AG - Segment focus
Exhibit 88: Novartis AG - Key offerings
Exhibit 89: Novartis AG - Key customers
Exhibit 90: Validation techniques employed for market sizing
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY TYPE
- Market segmentation by type
- Comparison by type
- Genital diseases - Market size and forecast 2018-2023
- Urinary diseases - Market size and forecast 2018-2023
- Market opportunity by type
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Astellas Pharma Inc.
- AstraZeneca
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- Novartis AG
- Research methodology
- List of abbreviations
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ billions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global genitourinary drugs market pipeline: Overview
Exhibit 18: Global genitourinary drugs market pipeline: Overview
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Genital diseases - Market size and forecast 2018-2023 ($ billions)
Exhibit 22: Syphilis cases reported in US 2013-2017
Exhibit 23: Genital diseases - Year-over-year growth 2019-2023 (%)
Exhibit 24: Urinary diseases - Market size and forecast 2018-2023 ($ billions)
Exhibit 25: Urinary diseases - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ billions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ billions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ billions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ billions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Prevalence of various genitourinary cancers in US 2015
Exhibit 45: Prevalence rate of urinary incontinence in the geriatric population in the US (2010)
Exhibit 46: Global geriatric population in the last 5 years
Exhibit 47: Trending advanced diagnostics
Exhibit 48: Recent approvals of generic drugs
Exhibit 49: Devices for the treatment of genitourinary diseases
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Trending novel formulations
Exhibit 52: Vendor landscape
Exhibit 53: Landscape disruption
Exhibit 54: Vendors covered
Exhibit 55: Vendor classification
Exhibit 56: Market positioning of vendors
Exhibit 57: Astellas Pharma Inc. - Vendor overview
Exhibit 58: Astellas Pharma Inc. - Business segments
Exhibit 59: Astellas Pharma Inc. - Organizational developments
Exhibit 60: Astellas Pharma Inc. - Geographic focus
Exhibit 61: Astellas Pharma Inc. - Key offerings
Exhibit 62: Astellas Pharma Inc. - Key customers
Exhibit 63: AstraZeneca - Vendor overview
Exhibit 64: AstraZeneca - Business segments
Exhibit 65: AstraZeneca - Organizational developments
Exhibit 66: AstraZeneca - Geographic focus
Exhibit 67: AstraZeneca - Key offerings
Exhibit 68: AstraZeneca - Key customers
Exhibit 69: Eli Lilly and Company - Vendor overview
Exhibit 70: Eli Lilly and Company - Business segments
Exhibit 71: Eli Lilly and Company - Organizational developments
Exhibit 72: Eli Lilly and Company - Geographic focus
Exhibit 73: Eli Lilly and Company - Segment focus
Exhibit 74: Eli Lilly and Company - Key offerings
Exhibit 75: Eli Lilly and Company - Key customers
Exhibit 76: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 77: Johnson & Johnson Services, Inc. - Business segments
Exhibit 78: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 79: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 80: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 81: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 82: Johnson & Johnson Services, Inc. - Key customers
Exhibit 83: Novartis AG - Vendor overview
Exhibit 84: Novartis AG - Business segments
Exhibit 85: Novartis AG - Organizational developments
Exhibit 86: Novartis AG - Geographic focus
Exhibit 87: Novartis AG - Segment focus
Exhibit 88: Novartis AG - Key offerings
Exhibit 89: Novartis AG - Key customers
Exhibit 90: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
FEATURED COMPANIES
- Astellas Pharma Inc.
- AstraZeneca
- Eli Lilly and Company
- Novartis AG
- MORE
Global Genitourinary Drugs Market 2019-2023
The analyst recognizes the following companies as the key players in the global genitourinary drugs market: Astellas Pharma Inc., AstraZeneca, Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advent of biologics and gene theraphy.”
According to the report, one of the major drivers for this market is the rising geriatric population.
Further, the report states that one of the major factors hindering the growth of this market is the preference for substitute treatment options.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The analyst recognizes the following companies as the key players in the global genitourinary drugs market: Astellas Pharma Inc., AstraZeneca, Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advent of biologics and gene theraphy.”
According to the report, one of the major drivers for this market is the rising geriatric population.
Further, the report states that one of the major factors hindering the growth of this market is the preference for substitute treatment options.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
- Astellas Pharma Inc.
- AstraZeneca
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- Novartis AG
Note: Product cover images may vary from those shown
